NEW YORK (GenomeWeb) – CompanionDx Reference Lab and Rx Review Service are partnering in an effort to increase the use of pharmacogenomics testing under a deal announced today.

Specifically, the firms seek to increase the availability of qualified pharmacogenomic testing to healthcare institutions and doctor practices in order to improve patient therapy. "The partnership provides an opportunity to grow and expand market presence, bringing the benefits of pharmacogenomic testing to the entire healthcare industry," Rx Review Service President Jerry Wanio said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.